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ABSTRACT
Trabectedin (ET743,Yondelis,manufacturedby
Baxter Oncology GmbH, Halle/Westfalen,
Germany, for Janssen Products, LP, Horsham,
PA), derived from the marine ascidian,
Ecteinascidia turbinata, is a natural alkaloid with
multiple complex mechanisms of action. On 23
October 2015, 15 years after the results of thefirst
Phase 1 clinical trial using trabectedin for
chemotherapy-resistant solid malignancies was
reported, and 8 years after its approval in Europe,
the United States Food and Drug Administration
(USFDA) finally approved trabectedin for the
treatment of unresectable or metastatic
liposarcoma or leiomyosarcoma that has failed
a prior anthracycline-containing regimen.
Approval was based on the results of a pivotal
Phase 3 trial involving a 2:1 randomization of
518 patients (who were further stratified by soft
tissue sarcoma subtype), in which a significant
improvement in progression-free survival was
reported in the trabectedin-treated group vs. the
dacarbazine-treated group (p\0.001). In this
trial, the most common adverse reactions were
nausea, fatigue, vomiting, constipation,
anorexia, diarrhea, peripheral edema, dyspnea,
and headache, while the most serious were
neutropenic sepsis, rhabdomyolysis,
cardiomyopathy, hepatotoxicity, and
extravasation leading to tissue necrosis. The
most common grade 3–4 adverse events were
laboratory abnormalities ofmyelosuppression in
both arms and transient transaminitis in the
trabectedin arm. In a recent Phase 2 trial,
trabectedin had a similar outcome as
doxorubicin when given as a single agent in the
first-line setting. Studies are also being
conducted to expand the use of trabectedin not
only as a first-line cancer drug, but also for a
number of other clinical indications, for
example, in the case of mesenchymal
chondrosarcoma, for which trabectedin has
been reported to be exceptionally active. The
possibility of combining trabectedin with
targeted therapies, immune checkpoint
inhibitors or virotherapy would also be an
interesting concept. In short, trabectedin is an
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OVERVIEW
Soft tissue sarcoma is a rare tumor of the
mesenchymal tissue, with many histological
subtypes. It comprises about 1% of all adult
cancers. The American Cancer Society estimated
that in the USA in 2015, about 11,930 new cases
would be diagnosed and 4870 Americans would
die of soft tissue sarcomas [1]. The most common
types of sarcoma in adults are undifferentiated
pleomorphic sarcoma (formerly known as
malignant fibrous histiocytoma), liposarcoma,
and leiomyosarcoma. There is a tendency for
certain types of sarcoma to originate from
specific anatomic sites, such as the abdomen for
leiomyosarcoma or the extremities for
liposarcoma and undifferentiated pleomorphic
sarcoma [2]. Surgical resection is the treatment of
choice for localizeddisease,withradiationgivenas
first-line therapy for unresectable cases.
Nonetheless, 50% of high-grade tumors tend to
recur [3]. For decades, treatment options for soft
tissue sarcoma have been limited to doxorubicin
and/or ifosfamide, and theoutcome formetastatic
disease is poor, with an estimatedmedian survival
of 8–13 months, as reported from results of
randomized studies conducted over the last
20 years [4–7]. Targeted therapies have recently
come of age for soft tissue sarcoma, with the
USFDAapprovalofpazopanib for locallyadvanced
unresectable ormetastatic soft tissue sarcomawith
the exception of liposarcoma in 2012. Approval
was based on the results of a randomized
placebo-controlled Phase 3 (PALETTE) trial
showing a significant, but modest, benefit in
progression-free survival (PFS) for patients treated
withpazopanib [8]. The approval of trabectedin in
the USA in late 2015 shows promise for further
improving the quality of life and progression-free
survival of patients with soft tissue sarcoma.
Trabectedin is a natural alkaloid derived from
the Caribbean tunicate, Ecteinascidia turbinata. It
has multiple complex mechanisms of action [2,
9–13] and consequently the potential for
extensive clinical applications. Further, several
features of trabectedin’s clinical performance
differentiate it from other oncologic agents.
These include prolonged tumor growth
stabilization, favorable outcomes in sarcomas
with genetic mutations, durability of response—
even upon treatment reinstitution after
interruption of therapy, and absence of
cumulative toxicity [14]. This article reports on
the critical stages of drug development of
trabectedin in the US and worldwide and
provides perspectives on its future as a uniquely
effective oncologic agent for soft tissue sarcomas
and other solid malignancies.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
CRITICAL STAGES OF TRABECTEDIN
DRUG DEVELOPMENT
Preclinical Studies
Trabectedin, derived from the marine tunicate,
Ecteinascidia turbinata, has multiple complex
mechanisms of action. In preclinical studies,
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trabectedin has been shown to bind to the N2
amino group of guanine residues in the minor
groove of the DNA double helix and cause
double-strand breaks [2, 9, 10]. Second,
trabectedin interrupts the cell cycle, causes
apoptosis of cancer cells and downregulates
abnormal transcription factor expression such
as FUS-CHOP or EWS-CHOP [10]. Third,
trabectedin inhibits cytokine release by
monocytes and macrophages in the tumor
microenvironment via its direct cytotoxic
effects on tumor-associated macrophages [11,
12]. This drug effect on the tumor
microenvironment is deemed critically
important in cancer therapy because of the
resultant inhibition of neoangiogenesis and the
metastatic potential of cancer cells [13].
Clinical Studies
Efficacy Studies
Table 1 lists selected Phase 1 clinical trials using
trabectedin for advanced solid tumors and the
Phase 2 and 3 studies for soft tissue sarcoma,
including retrospective analytical reports and
data from the expanded access program. There
are more studies of trabectedin conducted for
other clinical indications that are not listed in
the tables.
Phase 1 Studies
The goal of the Phase 1 clinical trials, which
involved patients with advanced solid
malignancies, was to determine the
dose-limiting toxicity and maximum tolerated
dose of trabectedin as well as to evaluate its
pharmacokinetics, pharmacodynamics, and
potential for adverse drug reactions. There
were at least seven reported Phase 1 studies
using trabectedin as a single agent for advanced
solid tumors [15–21] and five Phase 1 studies
using trabectedin in combination with either
doxorubicin, doxil, gemcitabine, or cisplatin
(Table 1) [22–26].
In 2001, Delaloge et al. [16] first reported
on the clinical activity of trabectedin in 29
patients with soft tissue sarcoma who had
failed treatment with doxorubicin and one
other chemotherapeutic agent (12 from a
phase 1 trial and 17 from a compassionate
use program cohort). In this study, there were
4/29 partial responses (PR), 2/29 minor
responses with tumor reduction of at least
30% in both cases, and 10/29 stable disease
(SD) lasting more than 2 months and median
time to progression of 2.8 months. In the
same year, Taama et al. [17] determined the
optimal regimen of trabectedin to be 1.5 mg/
m2 as a 24-h continuous intravenous infusion
once every 3 weeks from a Phase 1 study
involving 52 patients. Trabectedin was
characterized by a moderate plasma clearance
(31.5 and 37.5 l/h in the absence and presence
of coadministered dexamethasone,
respectively) and a large volume of
distribution at steady state (in excess of
5000 l) [27]. The biologic half-life of
trabectedin ranged from 27 to 89 h in
pharmacokinetic studies [15, 18, 19],
depending on the mode of administration
and infusion schedule. The terminal half-life
calculated using data from 14 Phase 1 and
Phase 2 studies using non-linear mixed effects
models was longer, in the range of 175 h [27].
Of the five Phase 1 studies using trabectedin
and one other chemotherapeutic agent, the
most promising combination regimen in
advanced soft tissue sarcomas (STS) and breast
cancer was trabectedin with doxorubicin, with
an overall response rate (ORR) of 18%, SD of
56%, and disease control rate (DCR) of 74%
[26].
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Phase 2 Studies
The goal of the Phase 2 clinical trials was to
evaluate the safety and efficacy of trabectedin at
the recommended dosage and mode of
administration derived from the results
obtained from Phase 1 trials in a larger
number of patients with STS who have failed
standard chemotherapy. Some investigators
reported on the use of trabectedin in the
first-line and the neoadjuvant settings. At least
nine Phase 2 clinical studies have been
conducted worldwide (Table 1) [28–36]. The
efficacy and safety of trabectedin in soft tissue
sarcoma are based on a randomized trial,
STS-201, in patients with locally advanced or
metastatic lipo- or leiomyosarcoma, whose
disease had progressed or relapsed after
treatment with at least anthracyclines and
ifosfamide. Additionally, in 2005, Le Cesne
and the EORTC [32] reported the results of a
Phase 2 study using trabectedin at 1.5 mg/m2
CIV in 104 patients. In that study, there were 8
(7.7%) PRs and 45 (43.3%) SDs. After a median
follow-up of 34 months, the median PFS was
3.4 months, and the median overall survival
was 9.2 months. The results of these Phase 2
trials led to the accelerated approval of
trabectedin by the European Union for
advanced soft tissue sarcoma in 2007. The best
Phase 2 results were reported by Monk et al. [34]
in 2012, with a PFS of 5.8 months in patients
with uterine leiomyosarcoma.
Retrospective Studies
At least five retrospective studies were
conducted between 2006 and 2015 [37–41].
One study involved the analysis of 885
patients from 25 French centers using
trabectedin at 1.5 mg/m2 as CIV infusion for
24 h every 3 weeks [41]. In this study, the
reported ORR was 17%, with a DCR of 67%,
PFS of 4.4 months, and median overall survival
(OS) of 12.2 months. In a report by Grosso et al.
(2007) [39], retrospective analysis of patients
with myxoid liposarcoma in five European and
American institutions showed an ORR of 51%,
DCR of 90%, and median PFS of 14 months. In
2011, San Filippo et al. [40] reported a PR of
16%, SD of 35%, and PFS of 3.3 months in
patients with uterine leiomyosarcoma.
Phase 3 Studies
Two Phase 3 randomized clinical trials were
conducted. One study compared the efficacy of
trabectedin vs. doxorubicin in
translocation-related sarcomas [42]. The other
compared the PFS using trabectedin vs.
dacarbazine [43].
The Phase 3 randomized study comparing
doxorubicin and trabectedin as first-line
therapy for translocation-related sarcomas
enrolled 121 patients and reported no
significant difference in PFS or OS between the
two arms of the trial, with the response rate by
response criteria in solid tumors (RECIST)
significantly higher in the doxorubicin arm
(27%) compared to the trabectedin arm
(5.9%). Consequently, doxorubicin remains
the first-line treatment for
translocation-related sarcoma. It is important
to note, however, that the study was
underpowered because of the high censoring
rate and high rate of ineligible patients.
In the pivotal Phase 3 study using trabectedin
vs. dacarbazine in locally advanced, unresectable,
or metastatic leiomyosarcoma and liposarcoma,
patients were randomized at a 2:1
trabectedin:dacarbazine ratio. The study
enrolled a total of 518 patients, with 345
randomized to the trabectedin arm and 173 to
the dacarbazine arm [43]. Trabectedin was given
at a dose of 1.5 mg/m2 as a 24-hCIV every 3weeks
and dacarbazine at 1000 mg/m2 IV over 20 to
120 min every 3 weeks. The median patient age
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was 56 years (range 17–81), and 30% were male,
77% white, 12% black, and 4% Asian. The study
was further stratified based on subtype
(leiomyosarcoma vs. liposarcoma), Eastern
Cooperative Oncology Group (ECOG) score (0 or
1), and number of previous chemotherapies (1 vs.
2 or more). Previous chemotherapy included
doxorubicin and ifosfamide, or doxorubicin or
ifosfamide and one other drug. Doxorubicin was
used in 90% of cases, gemcitabine in 81%,
docetaxel in 74%, ifosfamide in 59%, and
pazopanib in 10%. Seventy-three percent of
patients had leiomyosarcoma, and 27% had
liposarcoma. Forty-nine percent had an ECOG
score of 0, and 89% had two prior chemotherapy
regimens. Median PFS for trabectedin vs.
dacarbazine was 4.2 and 1.5 months,
respectively (hazard ratio, 0.55; p\0.001). Based
on a significant improvement in PFS for the
trabectedin arm, the USFDA gave full marketing
approval of trabectedin for leiomyosarcoma and
liposarcoma on 23 October 2015.
Expanded Access Program
The expanded access program for advanced soft
tissue sarcomas following failure of prior
chemotherapy enrolled 1895 patients
worldwide (Table 1) [44]. Analysis of the data
revealed that patients with leiomyosarcoma and
liposarcoma had a higher ORR (6.9% vs. 4%,
respectively) and significantly longer OS (16.2
vs. 8.4 months, respectively) than all other
histological subtypes. Patient enrollment has
continued beyond this publication.
Toxicity Studies
The adverse events reported in the Phase 3 trial
of trabectedin vs. dacarbazine in
leiomyosarcoma and liposarcoma patients who
had failed at least one anthracycline-based
regimen and one of another chemotherapeutic
agent are listed in the USFDA Product
Information document [45]. The most
common adverse reactions occurring in greater
than 10% of patients, and at a higher incidence
than the control arm receiving dacarbazine,
include nausea in 75%, fatigue in 69%,
vomiting in 46%, constipation and decreased
appetite in 37%, and diarrhea in 35%. Less
common adverse reactions were dyspnea and
headache in 25%, arthalgia and insomnia in
15%, and myalgia in 12%. Grade 3–4 adverse
reactions were uncommon (\10%). The most
common laboratory abnormalities include
anemia in 96%, increased alanine
aminotransferase (ALT), aspartate
aminotransferase (AST), and alkaline
phosphatase levels in 90, 84, and 70%,
respectively, neutropenia in 66%,
hypoalbuminemia in 63%, thrombocytopenia
in 59%, increased creatine phosphokinase in
33%, and hyperbilirubinemia in 13%. Among
the common grade 3–4 adverse events ([10%)
were neutropenia in 43%, thrombocytopenia in
21%, anemia in 19%, and increased ALT and
AST levels in 31% and 17%, respectively.
An important factor in reducing toxicity is
the use of dexamethasone as pre-medication
before starting trabectedin infusion. In a
previous study by Grosso et al., the incidence
of grade 3–4 liver enzyme elevation,
neutropenia, and thrombocytopenia fell to 3,
10, and 0%, respectively, in patients who
received routine antiemetic prophylaxis with
steroids on day 0 and possibly on day ?1,
compared with 70, 39, and 35%, respectively, in
the group who received dexamethasone
prophylaxis 4 mg PO BID the day before
trabectedin infusion (p = 0.0001) [46, 47].
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TRABECTEDIN APPLICATIONS
IN THE CLINIC
In the European Union, trabectedin (Yondelis
manufactured by Baxter Oncology GmbH,
Halle/Westfalen, Germany, for Janssen
Products, LP, Horsham, PA) gained marketing
approval for ovarian cancer and soft tissue
sarcoma under ‘‘exceptional circumstances’’
from the European Commission in September
2007 based on favorable results of Phase 2
studies [48]. The following is a summary of the
European Public Assessment Report (EPAR) for
trabectedin, which explained the process used
by the Committee for Medicinal Products for
Human Use (CHMP) in granting marketing
approval and provided recommendations for
optimum drug administration. For soft-tissue
sarcoma, patients who received trabectedin at
1.5 mg/m2 every 3 weeks had an average of
3.8 months PFS compared with 2.1 months in
patients who received a lower dose—three times
per month. For ovarian cancer, patients who
received the combination of trabectedin and
pegylated liposomal doxorubicin (PLD) had a
longer average PFS (7.3 months) compared to
those patients who received PLD alone
(5.8 months). In these Phase 2 studies, 10% of
patients treated with trabectedin as a single
agent and 25% treated with trabectedin in
combination therapy had serious side effects.
The most common side effects of any severity
were neutropenia, nausea, vomiting, increase in
liver enzymes, anemia, fatigue,
thrombocytopenia, anorexia, and diarrhea.
Trabectedin gained full marketing approval for
ovarian cancer and soft tissue sarcoma from the
European Commission in May 2015.
In the US, trabectedin (Yondelis,) gained
FDA approval on 23 October 2015 for
unresectable or metastatic liposarcoma or
leiomyosarcoma patients who received a prior
anthracycline-containing regimen [45]. The
recommended dose is 1.5 mg/m2 administered
as a continuous intravenous infusion over 24 h
through a central venous line every 21 days in
patients with normal bilirubin and AST or ALT
B2.5 times the upper limit of normal. Since
there was no evidence of cumulative toxicity in
the Phase 3 clinical trials, trabectedin may be
given until disease progression or
unacceptable toxicity occurs. There is no
recommended dose of trabectedin in patients
with serum bilirubin levels above the
institutional upper limit of normal. The
product information recommends
premedication with 20 mg dexamethasone
intravenous over 30 min prior to each
trabectedin dose to reduce documented liver
toxicity [45, 46].
Based on the toxicity profile of trabectedin,
the USFDA product information [45]
recommends dose modifications for
neutropenia, thrombocytopenia, elevated
bilirubin, serum transaminases, and creatine
phosphokinase, decreased left ventricular
ejection fraction or clinical evidence of
cardiomyopathy, or any grade 3 or 4
non-hematologic adverse reactions. The first
recommended dose reduction is to 1.2 mg/m2
every 3 weeks, the second to 1.0 mg/m2 every
3 weeks. Once reduced, the dose of trabectedin
should not be increased in subsequent
treatment cycles. Recommended dose
modifications include permanently
discontinuing trabectedin for persistent
adverse reactions requiring a delay in dosing
of more than 3 weeks, for adverse reactions
requiring dose reduction following trabectedin
administered at 1.0 mg/m2, and for severe liver
dysfunction in the prior treatment cycle.
Drug interactions can also occur between
trabectedin and cytochrome CYP3A inhibitors
or inducers. Therefore, the use of strong CYP3A
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inhibitors (e.g., oral ketoconazole, itraconazole,
posaconazole, voriconazole, clarithromycin,
telithromycin, indinavir, lopinavir, ritonavir,
boceprevir, nelfinavir, saquinavir, telaprevir,
nefazodone, and conivaptan) should be
avoided in patients taking trabectedin.
Grapefruit or grapefruit juice should also be
avoided during trabectedin treatment, as well as
the use of strong cytochrome CYP3A inducers
such as rifampin, phenobarbital, and St. John’s
wort [45].
THE FUTURE OF TRABECTEDIN
In the European Union, trabectedin has been
approved for ovarian cancer and soft tissue
sarcoma. Given that USFDA approval of
trabectedin is limited to only two subtypes of
soft tissue sarcoma, i.e., unresectable or
metastatic liposarcoma or leiomyosarcoma
patients who received a prior
anthracycline-containing regimen, trials for
other types of sarcoma that respond well to
trabectedin, such as mesenchymal
chondrosarcoma, will provide additional data
to support its use in the absence of an
FDA-approved clinical indication.
Evidence to support the use of trabectedin in
mesenchymal chondrosarcoma involves the
reported positive results of a single-center
retrospective analysis of patients treated in
various IRB-approved trials [49]. The objective
was to examine the clinical benefit of trabectedin
to various chondrosarcoma subtypes in a cohort
of patients with advanced unresectable disease.
Patients included in this retrospective analysis
received trabectedin administered at doses of
1.2–1.5 mg/m2 by 24-h infusion every 3 weeks.
Tumor response was evaluated from serial scans
(computed tomography/magnetic resonance
imaging/positron emission tomography) by
RECIST 1.1 criteria every 8 weeks. Treatment
adverse effects were assessed by clinical
evaluation and laboratory investigations.
Briefly, there were a total of 18 patients
studied: 5 with conventional chondrosarcoma,
5 with mesenchymal chondrosarcoma, 5 with
myxoid chondrosarcoma, and 3 with
de-differentiated chondrosarcoma. Mean age
was 53 years with a male-to-female ratio of
11:7. Adverse events were as follows: 33% of
patients had CTCAE grade 3–4
thrombocytopenia at least once; 11% had
grade 3–4 neutropenia not associated with
febrile episodes; one patient had grade 3–4
anemia; one patient had grade 3–4 elevated
liver enzymes; none developed cardiotoxicity or
nephrotoxicity during treatment; one patient
discontinued treatment because of port
infiltration after one cycle. Treatment dosage
was reduced in 10 of 18 (56%) patients in
response to adverse events and side effects.
Analyses of the safety and efficacy of
trabectedin use in mesenchymal
chondrosarcoma are as follows: (1) patients
with mesenchymal chondrosarcoma had a
higher median PFS and percentage PFS at 3
and 6 months than patients with other
chondrosarcoma subtypes, (2) trabectedin has
manageable hematological side effects and did
not result in any cardiotoxicity or
nephrotoxicity in our cohort, and (3) there
was no evidence of cumulative toxicity even
with prolonged duration of treatment.
Other promising studies include a recent
report of trabectedin activity in patients with
translocation-related sarcomas. In this Phase 2
open-label randomized study, trabectedin was
compared with best supportive care as second or
later line treatment. A total of 76 patients were
enrolled with 73 evaluable patients. Median PFS
was 5.6 months for trabectedin-treated patients
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vs. 0.9 months for patients who received best
supportive care (p\0.0001). These data suggest
a significant increase in PFS in
trabectedin-treated patients compared to those
who received best supportive care [50]. A
number of clinical trials are ongoing using
combination regimens of trabectedin with
olaparib [a poly (ADP-ribose) polymerase
(PARP) inhibitor] or with radiotherapy [51].
Retrospective analysis of patients treated with
trabectedin in second- and third-line settings
shows a trend toward earlier treatment with
trabectedin [52]. Prospective investigations
could include combination regimens with
trabectedin and promising chemotherapeutic
agents, such as eribulin and aldoxorubicin.
Cancer immunotherapy is also coming of age,
and combination regimens of trabectedin—to
expose tumor neoantigens in the TME—with
immune checkpoint inhibitors and/or oncolytic
viruses expressing granulocyte macrophage
colony stimulating factor (GM-CSF) to
recognize the neoantigens, may evoke a
favorable immunologic response in certain
patients with soft tissue sarcomas.
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